Advanced search
Publication Cover
Clinical Ophthalmology Volume 10, 2016 - Issue
Submit an article Journal homepage
121
Views
25
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study

Pascale MassinOphthalmology Department, Lariboisière Hospital, Paris, FranceCorrespondence[email protected]
,
Ali ErginayOphthalmology Department, Lariboisière Hospital, Paris, France
,
Bénédicte DupasOphthalmology Department, Lariboisière Hospital, Paris, France
,
Aude CouturierOphthalmology Department, Lariboisière Hospital, Paris, France
&
Ramin TadayoniOphthalmology Department, Lariboisière Hospital, Paris, France
Pages 1257-1264 | Published online: 08 Jul 2016

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Yusuf Mushtaq, Maryam M Mushtaq, Zisis Gatzioufas, Matteo Ripa, Lorenzo Motta & Georgios D Panos. (2023) Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies. Drug Design, Development and Therapy 17, pages 961-975.
Read now
Sarah E. Holden, Maged Habib & Craig J. Currie. (2020) Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. Current Medical Research and Opinion 36:6, pages 959-965.
Read now
Habiba Saedon, Astha Anand & Yit C Yang. (2017) Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clinical Ophthalmology 11, pages 583-590.
Read now
Craig J. Currie, Sarah E. Holden & David R. Owens. (2017) Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 33-43.
Read now
Sarah E. Holden, Craig J. Currie & David R. Owens. (2017) Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 5-17.
Read now
Daniele Veritti, Valentina Sarao, Laura Diplotti, Francesco Samassa & Paolo Lanzetta. (2017) Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Opinion on Pharmacotherapy 18:14, pages 1507-1516.
Read now

Articles from other publishers (19)

Xue Wu, Mengying Tao, Ling Zhu, Ting Zhang & Ming Zhang. (2022) Pathogenesis and current therapies for non-infectious uveitis. Clinical and Experimental Medicine 23:4, pages 1089-1106.
Crossref
Emily Rogalski, Angela Roberts, Elizabeth Salley, Marie Saxon, Angela Fought, Marissa Esparza, Erin Blaze, Christina Coventry, Marek-Marsel Mesulam, Sandra Weintraub, Aimee Mooney, Becky Khayum & Alfred Rademaker. (2022) Communication Partner Engagement: A Relevant Factor for Functional Outcomes in Speech–Language Therapy for Aphasic Dementia. The Journals of Gerontology: Series B 77:6, pages 1017-1025.
Crossref
Sarah Lebrize, Louis Arnould, Abderrahmane Bourredjem, Catharina Busch, Matus Rehak, Pascale Massin, Joao Barbosa-Breda, Marco Lupidi, Cesare Mariotti, Mahmoud Hamza, Alice Grise-Dulac, Pierre-Henry Gabrielle, Stephanie Baillif & Catherine Creuzot-Garcher. (2022) Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries. Ophthalmology and Therapy 11:3, pages 1217-1229.
Crossref
Patricia Udaondo, Mariacristina Parravano, Stela Vujosevic, Dinah Zur & Usha Chakravarthy. (2022) Update on Current and Future Management for Diabetic Maculopathy. Ophthalmology and Therapy 11:2, pages 489-502.
Crossref
Argyrios Chronopoulos, Panagiotis Chronopoulos, Agharza Ashurov, Christina Korb, Norbert Pfeiffer & Lars-Olof Hattenbach. (2021) Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results. European Journal of Ophthalmology 32:1, pages 443-449.
Crossref
Yohei Tomita, Deokho Lee, Kazuo Tsubota, Kazuno Negishi & Toshihide Kurihara. (2021) Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy. Journal of Clinical Medicine 10:20, pages 4666.
Crossref
Josh O. Wallsh & Ron P. Gallemore. (2021) Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells 10:5, pages 1049.
Crossref
Laurent Kodjikian, Stephanie Baillif, Catherine Creuzot-Garcher, Marie-Noëlle Delyfer, Frédéric Matonti, Michel Weber & Thibaud Mathis. (2021) Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review. Pharmaceutics 13:1, pages 72.
Crossref
Maria Vittoria Cicinelli, Alessandro Rabiolo, Piero Zollet, Luigi Capone, Rosangela Lattanzio & Francesco Bandello. (2020) Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management. American Journal of Ophthalmology 215, pages 14-24.
Crossref
Albert J Augustin, Silvia Bopp, Martin Fechner, Frank Holz, Dirk Sandner, Andrea-M Winkgen, Ramin Khoramnia, Thomas Neuhann, Marcus Warscher, Martin Spitzer, Walter Sekundo, Berthold Seitz, Tobias Duncker, Christian Ksinsik, Helmuth Höh & Daniela Gentsch. (2019) Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN ® (0.19 mg fluocinolone acetonide implant) . European Journal of Ophthalmology 30:2, pages 382-391.
Crossref
Raquel Estebainha, Raquel Goldhardt & Manuel Falcão. (2020) A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes. Current Ophthalmology Reports 8:1, pages 1-10.
Crossref
Fernanda P. Pons-Faudoa, Andrea Ballerini, Jason Sakamoto & Alessandro Grattoni. (2019) Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomedical Microdevices 21:2.
Crossref
Horace Massa, Anindyt M. NagarAthanasios Vergados, Panagiotis Dadoukis, Sudeshna Patra & Georgios D. Panos. (2018) Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review. Journal of International Medical Research 47:1, pages 31-43.
Crossref
Francesco Bandello, Rosangela Lattanzio, Ilaria Zucchiatti, Alessandro Arrigo, Marco Battista & Maria Vittoria Cicinelli. 2019. Clinical Strategies in the Management of Diabetic Retinopathy. Clinical Strategies in the Management of Diabetic Retinopathy 97 183 .
William Fusi-Rubiano, Rebecca R. Blow, Mark Lane, Rupal Morjaria & Alastair K. Denniston. (2018) Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review. Ophthalmology and Therapy 7:2, pages 293-305.
Crossref
Rita Santos Gonçalves, Carla Teixeira & Pedro Coelho. (2018) Rezidivierendes diabetisches Makulaödem: Was tun?. Kompass Ophthalmologie 4:3, pages 161-166.
Crossref
Rita Santos Gonçalves, Carla Teixeira & Pedro Coelho. (2017) Recurrent Diabetic Macular Edema: What to Do. Case Reports in Ophthalmology 8:3, pages 465-474.
Crossref
Yahiya Y. Syed. (2017) Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema. Drugs 77:5, pages 575-583.
Crossref
Michael W. StewartMichael W. Stewart. 2017. Diabetic Retinopathy. Diabetic Retinopathy 239 256 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.